Hyundai Pharmaceutical Co., Ltd.
004310.KSFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
11/30/2024
Revenue
132
Cost of Revenue
77
Gross Profit
55
Gross Margin
41.7%
Operating Income
0
Operating Margin
0.1%
Net Income
-0
Net Margin
-0.3%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
3
EBITDA Margin
2.2%
2023
11/30/2023
Revenue
136
Cost of Revenue
79
Gross Profit
56
Gross Margin
41.6%
Operating Income
5
Operating Margin
3.8%
Net Income
5
Net Margin
3.4%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
10
EBITDA Margin
7.3%
2022
11/30/2022
Revenue
122
Cost of Revenue
70
Gross Profit
52
Gross Margin
42.3%
Operating Income
6
Operating Margin
4.9%
Net Income
-0
Net Margin
-0.1%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
8
EBITDA Margin
6.2%
2021
11/30/2021
Revenue
105
Cost of Revenue
63
Gross Profit
42
Gross Margin
40.3%
Operating Income
-1
Operating Margin
-0.6%
Net Income
-2
Net Margin
-2.3%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
0
EBITDA Margin
0.2%
2020
11/30/2020
Revenue
100
Cost of Revenue
56
Gross Profit
44
Gross Margin
43.9%
Operating Income
2
Operating Margin
2.3%
Net Income
2
Net Margin
1.6%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
6
EBITDA Margin
5.5%